Methanogenic archaea

Methanogenic archaea are a specialized group of anaerobic microorganisms that produce methane as a metabolic byproduct through a process known as methanogenesis (Gaci et al., 2014). In the human gut, the most prominent species is Methanobrevibacter smithii, which plays a critical role in metabolic homeostasis by consuming hydrogen gas produced during bacterial fermentation (Dridi et al., 2011). However, an overabundance of these organisms and the resulting methane production are linked to clinical conditions such as constipation-predominant irritable bowel syndrome (IBS-C) and obesity, as methane acts as a gasotransmitter that slows intestinal transit and increases energy harvest (Pimentel et al., 2006; Mathur et al., 2013). Therapeutic interventions target these archaea using drugs like lovastatin, which inhibits the archaeal HMG-CoA reductase or the methyl-coenzyme M reductase complex to suppress methane production (Gottlieb et al., 2016). While they are a focus of drug development, Methanogenic archaea refers to a broad taxonomic group rather than a specific molecular target, making it a complex entity for traditional drug-receptor modeling.

Other names

MethanogensMethane-producing archaeaArchaeal methanogens

Inhibition of the HMG-CoA reductase enzyme or the methyl-coenzyme M reductase (MCR) complex, which are essential for archaeal cell wall synthesis and methane production, respectively.